Projects per year
© The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2016. This work reports the synthesis and characterization of palladium(ii) complexes Pd(L1)2 (1), Pd(L2)2 (2), Pd(L3)2 (3) and Pd(L4)2 (4), where L1H: 1-naphthaldehyde thiosemicarbazone; L2H: 4-phenyl-(1-naphthaldehyde)thiosemicarbazone; L3H: (2-hydroxy-1-naphthaldehyde)thiosemicarbazone; L4H: 4-phenyl-1-(2-hydroxy-1-naphthaldehyde)thiosemicarbazone. All four complexes show in vitro antiproliferative activity against the following human tumor cell lines: H460, DU145, MCF-7, M14, HT-29, K562, and HuTu 80. In particular Pd(L1)2 has the most potent activity for all the studied cell lines (IC50 ∼ 1 μM), with the exception of H460. Pd(L2)2 is a promising candidate as a pharmacological agent, since it presents a significant activity and is more innocuous than cisplatin against mouse fibroblast normal cells, 3T3. Pd(L4)2 is the complex which exhibits the lowest activity against the same cell line (IC50 ∼ 11 μM), being ten times lower than that of Pd(L1)2. These complexes were used to functionalize chitosan coated superparamagnetic magnetite nanoparticles with a metallic core of 11-13 nm, and the activity of these functionalized nanoparticles (NPs) against diverse human tumor cell lines was also tested. The nanoparticles functionalized with Pd(L1)2, Pd(L3)2 and Pd(L4)2 show antiproliferative activity against DU-145, while those with Pd(L2)2, Pd(L3)2 and Pd(L4)2 against HuTu80.
QMI: New complexes of platinum (II) and palladium (II) with derivatives of furan-2-carbaldehyde thiosemicarbazone and their antitumor activity
1/04/21 → 31/03/22